Workstream Type: Data Analysis
-
Xeljanz, the FDA, and nine years of patient harm
Read More
-
Atypical antipsychotics: Decades of use, unfathomable harms
Read More
-
Value-Based Management of Specialty Drugs: Practical Considerations and Implications for Pharmacy
Read More
-
Curbing Biologic Drug Spending with P-quad
Read More
-
Ethics of Clinical Trials to Evaluate Biosimilars
Read More
-
Bottom-Up Pricing Estimate for P-quad
Read More
-
Modeling P-quad
Read More
-
Priceless Knowledge: Attitudes and Awareness Around Drug Pricing Among US Medical Students
Read More
-
Research on the current state of US drug pricing and its effects
Read More
-
Analysis of Medicare Part D Plans Shows $9B Upcharge
Read More